Why This Blend Is So Widely Studied
The CJC-1295 + Ipamorelin combination is one of the most-researched peptide stacks in the growth hormone secretagogue (GHS) category. Together they target two different points in the GH release pathway — CJC-1295 as a growth hormone releasing hormone (GHRH) analogue, and ipamorelin as a growth hormone releasing peptide (GHRP) acting on ghrelin receptors.
The theoretical rationale: hitting both the GHRH and ghrelin receptor pathways simultaneously produces a more robust and physiologically natural GH pulse than either compound alone. This article breaks down what the animal model research and limited human data actually show.
The Individual Compounds
CJC-1295
CJC-1295 is a synthetic analog of GHRH (growth hormone releasing hormone), the natural hypothalamic peptide that signals the pituitary to release GH. Two versions exist:
- CJC-1295 with DAC (Drug Affinity Complex): Extended half-life (~6-8 days) via albumin binding
- CJC-1295 without DAC (often called Mod GRF 1-29): Short half-life (~30 min), produces more pulsatile GH release
The "blend" typically refers to CJC-1295 WITHOUT DAC combined with ipamorelin, designed to produce natural-pattern pulsatile GH release rather than elevated baseline GH levels.
Ipamorelin
Ipamorelin is a synthetic pentapeptide that binds ghrelin receptors (GHS-R1a) and stimulates GH release through a different mechanism than GHRH/CJC-1295. Key properties:
- High selectivity for GH release — doesn''t significantly affect cortisol or prolactin
- Short half-life (~2 hours)
- No appetite stimulation at typical doses (unlike stronger GHRPs like GHRP-6)
This selectivity is what distinguishes ipamorelin from older GHRPs — it produces GH release with minimal off-target effects.
The Synergy Rationale
Research suggests the two compounds work synergistically because they target different points in the GH cascade:
| Pathway | Effect |
|---|---|
| CJC-1295 (GHRH analog) | Stimulates somatotroph cells via GHRH receptor |
| Ipamorelin (ghrelin agonist) | Stimulates somatotroph cells via GHS-R1a |
| Combined | Simultaneous activation of both receptor systems produces amplified, pulsatile GH release |
Animal model research has documented that the combined effect exceeds the sum of either compound alone — a synergistic rather than additive response.
Molecular Properties
| Property | CJC-1295 (no DAC) | Ipamorelin |
|---|---|---|
| Molecular weight | 3,368 g/mol | 711.9 g/mol |
| Structure | 29 amino acids | 5 amino acids |
| Half-life (subq) | ~30 minutes | ~2 hours |
| Receptor target | GHRH receptor | Ghrelin receptor (GHS-R1a) |
| CAS number | 51753-57-2 (parent), various for mod | 170851-70-4 |
| Research status | Animal models + limited human | Animal models + limited human |
What the Research Actually Shows
Growth Hormone Release
Animal studies consistently show:
- Dose-dependent GH elevation after combined administration
- Sustained but pulsatile release pattern (more physiological than continuous elevation)
- Peak GH typically 15-30 minutes after subcutaneous administration
- Return to baseline within 2-3 hours
Human data is more limited but generally consistent with animal findings — the compounds produce measurable GH elevation in research subjects.
IGF-1 Effects
Downstream of GH is IGF-1 (insulin-like growth factor 1), which mediates many of GH''s anabolic effects. Animal models show:
- IGF-1 elevation following 4-12 weeks of combined administration
- The magnitude is dose-dependent
- Individual response varies significantly
Body Composition
Research in animal models of obesity and caloric restriction has suggested:
- Preserved lean mass during restricted feeding
- Reduced visceral fat accumulation
- Improved recovery from catabolic states
Human data specifically on the CJC-1295 + ipamorelin combination for body composition is sparse. Inferences often come from related GHRH/GHS research in clinical populations.
Sleep Architecture
Interestingly, research suggests GHRH analogs may influence sleep architecture — specifically slow-wave sleep. Some animal and early human research has documented increased deep sleep following GHRH administration, an effect distinct from the body composition applications.
Why Researchers Study the Blend Rather Than Either Alone
Several reasons the combination has more research traction than monotherapy:
- Physiological GH pulsatility: The short-acting CJC-1295 + short-acting ipamorelin produces pulsatile release, closer to natural GH rhythm
- Mechanism redundancy: Hitting two receptor systems reduces the variance in individual response
- Tolerability: Lower individual doses of each component may produce fewer side effects than high-dose monotherapy
- Avoiding receptor desensitization: Continuous elevation of GH-axis activity (as with high-dose GH or CJC-1295 WITH DAC) can desensitize receptors over time
Research Limitations
Important caveats:
- No FDA approval: Both compounds are research-grade only. Not approved for human therapeutic use.
- Limited human trial data: Most published research is animal models. Human data is primarily case reports and small research studies.
- Long-term safety unknown: No multi-year safety data in humans.
- GH is tightly regulated: Elevation of GH and IGF-1 has theoretical cancer and metabolic concerns. The cellular environment created by elevated GH/IGF-1 may promote growth of existing malignancies.
- Individual variability: Response varies significantly by age, baseline GH status, body composition, and other factors.
How Researchers Source Research-Grade Material
Research-grade CJC-1295 + Ipamorelin blend is available through vetted suppliers. We partner with two:
- Amino Club (use code PROTOSI) — US manufactured, CoA available
- Pantheon Peptides — partner-tracked, third-party testing
Both supply research-grade material. Pricing and availability vary.
Read our Amino Club supplier review for our full vetting breakdown.
Where It Fits in a Protocol
The CJC-1295 + Ipamorelin blend appears in our research stacks for:
- Body Composition: Intermediate and premium tier stacks
- Hormone Optimization: As part of GH-axis research
- Injury Recovery: Potential role in recovery contexts
See the relevant stack pages for complete research protocols combining peptides, supplements, devices, and baseline lab testing.
Baseline Testing Considerations
Any research involving GH-axis compounds typically includes baseline monitoring:
- IGF-1 serum levels: Key downstream marker
- HbA1c + fasting glucose: GH elevation can affect insulin sensitivity
- Comprehensive metabolic panel: Liver and kidney function
- Lipid panel + ApoB: GH affects lipid metabolism
See our Lab Testing research for the relevant panels.
Comparison with Other Research Options
If you''re researching GH-axis compounds, related options include:
- Tesamorelin (FDA-approved for HIV lipodystrophy, studied for visceral fat)
- Hexarelin (stronger GHRP than ipamorelin, less selective)
- CJC-1295 DAC alone (extended half-life, continuous rather than pulsatile GH)
- AOD-9604 (GH fragment, metabolic-focused)
Each has different research profiles and target applications.
The Bottom Line
The CJC-1295 + Ipamorelin combination is one of the most-discussed peptide research stacks for a reason: mechanistic synergy (two receptor pathways), tolerability (ipamorelin''s selectivity), and a growing if still limited body of research.
But it''s still primarily animal model evidence. Human trial data is limited. Long-term safety is unknown. Research protocols should involve qualified clinical supervision, baseline testing, and conservative dosing.
For research and educational purposes only. Not medical advice.
Want a personalized protocol?
Take the assessment and we'll match you to the right research stack based on your goals.
Start your assessment →